Supernus Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Supernus Pharmaceuticals stock.
View analyst ratings for Supernus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Supernus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Supernus Pharmaceuticals.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings results on Wednesday, August, 4th. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.17 by $0.26. The specialty pharmaceutical company had revenue of $141.33 million for the quarter, compared to the consensus estimate of $135.50 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 13.39% and a net margin of 17.55%. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.65 earnings per share.
View Supernus Pharmaceuticals' earnings history.

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SUPN stock has increased by 68.8% and is now trading at $27.26.
View which stocks have been most impacted by COVID-19.

Supernus Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $550 million-$580 million, compared to the consensus revenue estimate of $558.02 million.

2 Wall Street analysts have issued 1 year target prices for Supernus Pharmaceuticals' shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $37.50 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Omeros (OMER).
View all of SUPN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.32%), Armistice Capital LLC (6.25%), Dimensional Fund Advisors LP (4.28%), Macquarie Group Ltd. (4.02%), Renaissance Technologies LLC (2.85%) and Stephens Investment Management Group LLC (2.35%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends for Supernus Pharmaceuticals.

SUPN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, LSV Asset Management, Renaissance Technologies LLC, Ashford Capital Management Inc., Rice Hall James & Associates LLC, Armistice Capital LLC, Hussman Strategic Advisors Inc., and Marshall Wace LLP. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Stefan KF Schwabe, and Tami Tillotson Martin.
View insider buying and selling activity for Supernus Pharmaceuticals or view top insider-selling stocks.

SUPN stock was purchased by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Victory Capital Management Inc., Fuller & Thaler Asset Management Inc., International Biotechnology Trust PLC, Nuveen Asset Management LLC, Dimensional Fund Advisors LP, First Trust Advisors LP, and Stephens Investment Management Group LLC.
View insider buying and selling activity for Supernus Pharmaceuticals or or view top insider-buying stocks.

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SUPN stock can currently be purchased for approximately $27.26.

Supernus Pharmaceuticals has a market capitalization of $1.45 billion and generates $520.40 million in revenue each year. The specialty pharmaceutical company earns $126.95 million in net income (profit) each year or $2.36 on an earnings per share basis.

Supernus Pharmaceuticals employs 563 workers across the globe.

The official website for Supernus Pharmaceuticals is www.supernus.com.

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at (301) 838-2500 or via email at [email protected].